samedan logo
 
 
spacer
home > pmps > winter 2002 > packaging for stability testing of active substances
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Packaging for Stability Testing of Active Substances

Ideally any drug substance entered into a stability programme should be stored in the actual holding containers. However, those which properly represent the actual holding containers used during manufacture may also be used in the stability programme. Containers of reduced size may be acceptable for drug substance stability testing provided that they are constructed of the same material and use the same type of container closure system that is intended to be used during manufacture. The container closure system to be used in the packaging of an active substance must be justified for its intended use.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Kirsten Nielsen MSc, Head of the Pharmaceutical Packaging Development Department at LEO Pharma A/S
Kirsten Nielsen holds a position as Head of Department, Pharmaceutical Packaging Development at LEO Pharma A/S. She has been with the company for nine years. Prior to that she was with the Danish Packaging and Transportation Research Institute (ATV) after four years with Unilever. Throughout her career she has worked in packaging covering many aspects including production, quality control, research, development, testing, training and technology transfer.

Kirsten has also worked with the European Commission within her area of expertise. During her years at The Danish Packaging and Transportation Research Institute (ATV), Kirsten published her work at international conferences in Austria, Switzerland, Denmark, France, Norway and the US.

spacer
Kirsten Nielsen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement